<DOC>
	<DOCNO>NCT01253304</DOCNO>
	<brief_summary>The primary purpose study help answer follow research question , provide treatment condition : - To evaluate much study drug ( LY2189265 ) blood participant vary degree liver impairment compare normal liver function . - To assess safety LY2189265 side effect might associate .</brief_summary>
	<brief_title>A Single Dose Study LY2189265 Subjects With Varying Degrees Hepatic ( Liver ) Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<criteria>All Participants ( include participant type 2 diabetes mellitus [ T2DM ] ) : Male participant Agree use reliable method birth control ( example , barrier method ) study least 3 month follow dose study drug Female participant : Women must nonchildbearing potential due surgical sterilization ( hysterectomy , bilateral oophorectomy , tubal ligation ) menopause Women intact uterus deem postmenopausal 45 year old cessation menses least 1 year 6 12 month spontaneous amenorrhea follicle stimulate hormone ( FSH ) &gt; 40 international unit per milliliter ( IU/mL ) take hormone replacement therapy oral contraceptive within 1 year study start otherwise healthy Women cessation menses least 2 year permit take hormone replacement therapy Have body mass index ( BMI ) 19.0 40.0 kilogram per meter square ( kg/m^2 ) , inclusive , screen . Have venous access sufficient allow blood sampling Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly ethical review board govern site Control Participants : Overtly healthy participant normal hepatic function Participants T2DM normal hepatic function Have normal sit blood pressure pulse rate determine investigator change compatible age disease status case patient T2DM Have clinical laboratory test result within normal reference range investigator site result minor deviation consider clinically significant investigator change compatible age disease status case T2DM Hepatic Impaired Participants : Have stable hepatic impairment ( , postalcoholic , chronic hepatitis , biliary cirrhosis , cryptogenic ) classify ChildPugh Class A , B , C ( mild , moderate , severe impairment ) consider investigator acceptable participation study . The hepaticimpaired participant population may include patient T2DM . Have sit blood pressure pulse rate compatible disease state [ include T2DM , applicable ] determine investigator . Participants T2DM ( All Study Groups ) Have T2DM control diet exercise alone T2DM stable single , oral agent antihyperglycemic medication ( metformin , sulfonylurea , repaglinide , nateglinide , acarbose [ disaccharidase inhibitor ] , thiazolidinediones ) least 3 week ( 3 month thiazolidinediones ) prior admission Have glycosylated hemoglobin ( HbA1C ) value screening ( within 4 week prior screen ) 6.5 % 9.0 % Have clinical laboratory test result within normal range deem clinically insignificant investigator . Abnormalities serum glucose , serum lipid , urinary glucose , urinary protein consistent T2DM acceptable Have acceptable blood pressure pulse rate ( sit ) , determine investigator All participant ( include participant T2DM ) Are currently enrol , discontinue within last 30 day clinical trial involve use investigational drug device study drug , concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2189265 relate compound Have previously complete withdrawn study study investigate LY2189265 Have current , function organ transplant Show evidence significant active , uncontrolled , endocrine autoimmune abnormality ( , thyroid disease pernicious anemia ) judge screen physician Have show febrile illness within 3 day prior screen Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Regularly use know drug abuse and/or show positive finding urinary drug screen otherwise explain permit concomitant medication Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody Are woman positive pregnancy test woman lactate Have donate blood 500 milliliter ( mL ) within last month prior screen Have average weekly alcohol intake exceed 21 unit per week ( men ) 14 unit per week ( woman ) ( 1 unit = 12 ounce [ oz ] 360 mL beer , 5 oz 150 mL wine , 1.5 oz 45 mL distil spirit ) Are unwilling stop alcohol consumption duration study ( screen followup visit ) Are participant smoke 10 cigarette per day , unwilling refrain smoking day LY2189265 administration , unable abide clinical research unit ( CRU ) restriction inpatient day Have history presence pancreatitis ( history chronic pancreatitis idiopathic acute pancreatitis ) gastrointestinal disorder , ( example relevant esophageal reflux gall bladder disease , gastrointestinal disease impact gastric empty [ , gastric bypass surgery , pyloric stenosis , exception appendectomy ] could aggravate glucagon like peptide [ GLP ] analog ) . Participants mild hypertension dyslipidemia , participant cholecystolithiasis ( removal gall stone ) and/or cholecystectomy ( removal gall bladder ) past , sequela , may include study discretion screen physician . Are participant deem unsuitable investigator reason . Control participant : Have history presence cardiovascular ( , myocardial infarction , cerebrovascular accident , venous thromboembolism ) , respiratory , renal , endocrine ( exception participant T2DM ) , hematological , neurological disorder , cancer , hepatic ( include Gilbert 's disease ) , dermatological disorder diseases capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Show evidence significant active neuropsychiatric disease Have creatinine clearance le 80 milliliter per minute ( mL/min ) ( calculate CockcroftGault equation ) Show evidence hepatitis B and/or positive hepatitis B surface antigen Show evidence hepatitis C and/or positive hepatitis C antibody Intend use : Overthecounter medication ( include herbal remedies/health supplement ) within 7 day prior dose Prescription medication within 14 day prior dose participant mild , moderate , severe hepatic impairment Show evidence significant active disease responsible associate hepatic impairment . Participants hypertension hyperlipidemia may permit investigator 's discretion . Show , opinion investigator , evidence significant neuropsychiatric disease Grade 1 hepatic encephalopathy Show evidence spontaneous bacterial peritonitis within 6 month dose . Show evidence severe hyponatremia ( Sodium [ Na ] &lt; 120 millimoles per liter [ mmol/L ] ) Show presence hepatocellular carcinoma Have portal shunt Show evidence severe ascites Have hemoglobin &lt; 9.0 gram per deciliter ( g/dL ) Have platelet count &lt; 40 x 10^9 cell per liter ( cells/L ) Have total serum bilirubin &gt; 15 milligram per deciliter ( mg/dL ) Use medication know interfere hepatic metabolism ( , barbiturates , phenothiazine ) know alter major organ system Mild , Hepatic Impaired Participants ( ChildPugh A ) Show evidence active renal disease creatinine clearance &lt; 70 mL/min calculate CockcroftGault equation . Moderate Severe Hepatic Impaired Subjects ( ChildPugh B C ) Show evidence hepatorenal syndrome show creatinine clearance &lt; 50 mL/min calculate CockcroftGault equation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>